Mangoceuticals, Inc. - MGRX STOCK NEWS

Mangoceuticals, Inc. (NASDAQ:MGRX) announced on April 25, 2023, the start of an online sales campaign in partnership with DataDojo, employing their advanced Customer Data Platform (CDP) and AI technology. This initiative focuses on optimizing customer acquisition through the analysis of over 240 million consumer profiles and 5 million pre-loaded profiles provided by DataDojo. The campaign aims to enhance MangoRx's direct-to-consumer presence in the men's health sector, particularly for its erectile dysfunction product, Mango. CEO Jacob Cohen emphasized the potential for significant growth and marketing efficiencies from this collaboration. DataDojo claims that utilizing first-party data can halve customer acquisition costs and boost revenues by 5-15%. Key risks involving regulatory approvals for MangoRx’s products and competition are acknowledged, alongside the need for ongoing funding.

Mangoceuticals, Inc. (NASDAQ:MGRX), a company specializing in men's health products, has announced its participation on the Webull Corporate Communication services platform, enhancing direct communication with shareholders. This initiative aims to provide instant notifications regarding company updates, earnings reports, and investor presentations. Jacob Cohen, the company's co-founder and CEO, expressed excitement about utilizing Webull's mobile-first brokerage platform for efficient digital communication. The Company offers telemedicine services including its erectile dysfunction product branded 'Mango', positioning itself in a growing sector. Investors are encouraged to follow Mangoceuticals on Webull for real-time updates.

Mangoceuticals, Inc. (NASDAQ:MGRX) announced that its debut commercial has exceeded 5 million views on YouTube, just five months after its launch. The commercial promotes the company's erectile dysfunction product, Mango, through a humorous marketing approach aimed at reducing stigma surrounding men's health discussions. CEO Jacob Cohen stated that the success of the commercial reflects effective marketing strategies. Mangoceuticals focuses on developing and selling men's health products via a secure telemedicine platform, identifying the men's wellness sector, especially erectile dysfunction, as a growing market. However, the company faces various risks, including reliance on FDA approval and market competition.

Mangoceuticals, Inc. has strengthened its commitment to protecting shareholder interests by engaging Shareholder Intelligence Services for a 12-month agreement.

Their DRIL-Down^TM platform will analyze trading data to identify and combat potential illegal short selling of the company’s stock, following concerns of market manipulation.

This partnership aims to ensure fair market conditions and enhance transparency for MGRX investors.

Mangoceuticals focuses on developing men’s health products, including a unique erectile dysfunction treatment.

Mangoceuticals, Inc. (NASDAQ:MGRX) has successfully closed its initial public offering of 1,250,000 shares at $4.00 per share, resulting in gross proceeds of $5,000,000. The offering included a 45-day option for underwriters to purchase an additional 187,500 shares. The funds will be allocated toward marketing, operational expenses related to its ED drug, 'Mango,' personnel hiring, software development, and general corporate purposes. The common stock began trading on Nasdaq on March 21, 2023. Boustead Securities, LLC was the sole managing underwriter. The offering was registered with the SEC, effective March 20, 2023.

Mangoceuticals, Inc. has announced its initial public offering (IPO) of 1,250,000 shares at $4.00 each, generating gross proceeds of $5,000,000. The shares will commence trading on Nasdaq under the ticker symbol MGRX on March 21, 2023, with the offering expected to close on March 23, 2023. The company plans to utilize the funds for marketing its ED drug, 'Mango,' hiring personnel, software development, and general corporate purposes. Boustead Securities, LLC is the sole managing underwriter. A 45-day overallotment option for an additional 187,500 shares is also granted to underwriters.